1. US Food and Drug Administration (FDA). FDA announces preliminary assessment that certain naloxone products have the potential to be safe and effective for over-the-counter use: agency continues to encourage sponsor applications for their over-the counter naloxone products. Available at:https://www.fda.gov/news-events/press-announcements/fda-announces-preliminary-assessment-certain-naloxone-products-have-potential-be-safe-and-effective. Accessed December 31, 2022.
2. Cision PR Newswire. Harm reduction therapeutics' new drug application for RiVive™ over-the-counter naloxone nasal spray accepted and granted priority review by FDA. Available at:https://www.prnewswire.com/news-releases/harm-reduction-therapeutics-new-drug-application-for-rivive-over-the-counter-naloxone-nasal-spray-accepted-and-granted-priority-review-by-fda-301710002.html. Accessed December 31, 2022.
3. Jordan MR, Morrisonponce D. Naloxone. Treasure Island, FL: Stat Pearls Publishing; 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK441910. Accessed December 31, 2022.
4. Pulmonary complications of opioid overdose treated with naloxone;Farkas;Ann Emerg Med,2019
5. Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study;Chang;BMC Med,2018